GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (FRA:ASZ1) » Definitions » EV-to-FCF

Alimera Sciences (FRA:ASZ1) EV-to-FCF : -2.67 (As of May. 11, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alimera Sciences's Enterprise Value is €222.13 Mil. Alimera Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-83.06 Mil. Therefore, Alimera Sciences's EV-to-FCF for today is -2.67.

The historical rank and industry rank for Alimera Sciences's EV-to-FCF or its related term are showing as below:

FRA:ASZ1' s EV-to-FCF Range Over the Past 10 Years
Min: -42.36   Med: -7.42   Max: 136.06
Current: -2.67

During the past 13 years, the highest EV-to-FCF of Alimera Sciences was 136.06. The lowest was -42.36. And the median was -7.42.

FRA:ASZ1's EV-to-FCF is ranked worse than
100% of 511 companies
in the Drug Manufacturers industry
Industry Median: 23.55 vs FRA:ASZ1: -2.67

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Alimera Sciences's stock price is €3.225. Alimera Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.003. Therefore, Alimera Sciences's PE Ratio for today is At Loss.


Alimera Sciences EV-to-FCF Historical Data

The historical data trend for Alimera Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences EV-to-FCF Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.66 -27.25 -21.29 -7.63 -3.11

Alimera Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.63 -8.97 -1.69 -2.33 -3.11

Competitive Comparison of Alimera Sciences's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's EV-to-FCF falls into.



Alimera Sciences EV-to-FCF Calculation

Alimera Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=222.125/-83.063
=-2.67

Alimera Sciences's current Enterprise Value is €222.13 Mil.
Alimera Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-83.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alimera Sciences  (FRA:ASZ1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alimera Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.225/-2.003
=At Loss

Alimera Sciences's share price for today is €3.225.
Alimera Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Alimera Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (FRA:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (FRA:ASZ1) Headlines

No Headlines